| Date | Time | Source | Headline | Symbol | Company |
| 05/17/2024 | 3:00PM | iHub Newswire | FeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements | | |
| 05/16/2024 | 8:32AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/16/2024 | 8:32AM | PR Newswire (US) | Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/15/2024 | 8:38AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/15/2024 | 8:38AM | PR Newswire (US) | Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/14/2024 | 4:16PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/13/2024 | 10:53AM | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/13/2024 | 7:30AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/13/2024 | 7:30AM | PR Newswire (US) | Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/10/2024 | 4:30PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/09/2024 | 8:30AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/09/2024 | 8:30AM | PR Newswire (US) | Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/08/2024 | 8:45AM | PR Newswire (US) | Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/08/2024 | 8:31AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/07/2024 | 4:13PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/07/2024 | 8:55AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/07/2024 | 8:55AM | PR Newswire (US) | Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/02/2024 | 9:00AM | PR Newswire (US) | Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024 | NASDAQ:MBRX | Moleculin Biotech Inc |
| 05/01/2024 | 8:50AM | PR Newswire (US) | Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin | NASDAQ:MBRX | Moleculin Biotech Inc |
| 04/18/2024 | 8:30AM | PR Newswire (US) | European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) | NASDAQ:MBRX | Moleculin Biotech Inc |
| 04/10/2024 | 8:30AM | PR Newswire (US) | Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties | NASDAQ:MBRX | Moleculin Biotech Inc |
| 03/28/2024 | 10:45AM | PR Newswire (US) | Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference | NASDAQ:MBRX | Moleculin Biotech Inc |
| 03/27/2024 | 9:25AM | PR Newswire (US) | Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity | NASDAQ:MBRX | Moleculin Biotech Inc |
| 03/27/2024 | 9:05AM | PR Newswire (US) | Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML | NASDAQ:MBRX | Moleculin Biotech Inc |
| 03/25/2024 | 7:30AM | PR Newswire (US) | Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial | NASDAQ:MBRX | Moleculin Biotech Inc |
| 03/22/2024 | 4:05PM | PR Newswire (US) | Moleculin Reports Full Year 2023 Financial Results | NASDAQ:MBRX | Moleculin Biotech Inc |
| 03/20/2024 | 7:30AM | PR Newswire (US) | Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast | NASDAQ:MBRX | Moleculin Biotech Inc |
| 03/20/2024 | 7:15AM | IH Market News | JPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest News | NASDAQ:MBRX | Moleculin Biotech Inc |
| 03/19/2024 | 4:30PM | PR Newswire (US) | Moleculin Announces Reverse Stock Split | NASDAQ:MBRX | Moleculin Biotech Inc |
| 03/12/2024 | 9:05AM | PR Newswire (US) | Moleculin to Present at the 36th Annual ROTH Conference | NASDAQ:MBRX | Moleculin Biotech Inc |